Therapeutic Lifestyle Changes (TLC)

Therapeutic Lifestyle Changes (TLC) are recommended as a first line treatment for a variety of common health

problems by many national health organizations, including:

• National Institutes of Health (NIH)
• National Cholesterol Education Program (ATP III Guidelines)
• American Diabetes Association
• North American Menopause Society
• American Heart Association
• American Association of Clinical Endocrinologists
• And many others

Lifestyle-related, chronic health problems:

• Elevated Cholesterol Elevated Blood Pressure
• Cardiovascular Disease Overweight/Obesity
• Type 2 Diabetes Insulin Resistance or Metabolic Syndrome
• Osteoporosis Osteoarthritis
• Conditions related to aging

FirstLine Therapy® (FLT) is a therapeutic lifestyle changes (TLC) program that is clinically effective, yet easy to implement. FLT provides time-saving tools that make it easy for you to integrate recommendations for diet and exercise with medical foods and other lifestyle changes, in a format that patients can understand and follow.

Most importantly, patients get results with the FLT program. Many are able to achieve their risk-reduction goals without medication in as little as 12 weeks on FLT.

Moderate Risk Reduction

• Wellness EssentialsTM Cardiovascular Support - 2 packets daily

Wellness Essentials Cardiovascular Support is a combination of essential vitamins and minerals, omega-3 fatty acids, antioxidants, and phytonutrients to promote healthy cardiovascular function and overall well-being.

• CardioauxinTM - 2 tablets twice daily

CardioauxinTM  is a very efficacious lipid-lowering, heart risk reduction formula.  This formula contains

a unique combination of synergistic nutrients that proved to significantly lower low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG), while raising protective high-density lipoprotein cholesterol (HDL-C).

Therapeutic Lifestyle Change

• Low Glycemic Index diet (see FirstLine Therapy® Diet)
• Exercise - 150 min/wk of aerobic exercise (e.g. walking 30 min/day at 5 days/wk).

Severe Risk Reduction

• FirstLine Therapy® Program

FLT uses a low-glycemic-index dietary regimen and exercise program while incorporating medical foods and nutritional supplements. New research has shown that low glycemic diets are more

effective than low fat diets in treating obesity, insulin resistance, dyslipidemia, cardiovascular disease and type-2 diabetes.

• UltraMeal® Plus 360- 2 scoops twice daily

UltraMeal Plus 360 is a medical food formulated to provide specialized, multi-mechanistic

nutritional support for patients with metabolic syndrome and cardiovascular disease by supplying a combination of acacia extract, reduced iso-alpha acids (RIAA), plant sterols, and heart-healthy soy protein and isoflavones.

• EPA-DHA Extra Strength® - 2 to 4 softgels twice daily

Concentrated and Stabilized Purity-Certified, Omega-3 Fatty Acids

• CardioauxinTM - 2 tablets twice daily

Cardioauxin is a very efficacious lipid-lowering, heart risk reduction formula.

• Red Yeast Extract - 1 capsule three times daily

Taken orally, red yeast extract is used to reduce and maintain desirable cholesterol and lipoprotein

levels in hyperlipidemic individuals.

Clinical Note

If your patients are on cholesterol lowering drugs (e.g. statins), consider adding:

CoQ-10 ST-100TM - 1-2 softgels daily

CoQ-10 ST features 30 mg of a stabilized, all natural encapsulation of coenzyme Q10 (CoQ10) manufactured to achieve exquisite quality, purity, and bioavailability

The depletion of the essential nutrient CoQ10 by the increasingly popular cholesterol lowering drugs, HMG CoA reductase inhibitors (statins), has grown from a level of concern to one of alarm. With ever higher statin potencies and dosages, and with a steadily shrinking target LDL cholesterol, the prevalence and severity of CoQ10 deficiency

is increasing noticeably. An estimated 36 million Americans are now candidates for statin drug therapy. Statin- induced CoQ10 depletion is well documented in animal and human studies with detrimental cardiac consequences

in both animal models and human trials. This drug-induced nutrient deficiency is dose related and more notable

in settings of pre-existing CoQ10 deficiency such as in the elderly and in heart failure.1

Published data already indicated that statins can cause myopathies and rhabdomyolysis with renal failure. Moreover, on May 1, 2000, the FDA issued a warning about liver failure as an adverse reaction of statin use, based on reports that more than half of 62 patients with liver failure died.  An estimate claims that the drugs can cause liver and muscle injury in up to 1% of users.  For the US this will equal up to 130,000 patients with liver and muscle toxicity symptoms.  Moreover, statins use is also implicated the increased incidence of cataracts, neoplasia, peripheral neuropathies, and some psychiatric disturbances.2

Statin-induced CoQ10 deficiency is completely preventable with supplemental CoQ10 with no adverse impact

on the cholesterol lowering or anti-inflammatory properties of the statin drugs.1

References:

1.     Langsjoen PH, Langsjoen AM The clinical use of HMG CoA reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors 2003;18:101-111

2.     Bliznakov E. Lipid lowering drugs (statins), cholesterol, and coenzyme Q10: the Baycol case - a modern pandora's box. Biomed Pharmacother,

2002;56:56-9.